Navigation Links
NeurogesX to Report Fourth Quarter and Year-End 2007 Financial Results
Date:3/18/2008

SAN MATEO, Calif., March 18 /PRNewswire-FirstCall/ -- NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today announced it will report results for its fourth quarter and year-end 2007 on Wednesday, March 26, 2008, after the market closes.

A conference call to review the results will begin at 5:00 p.m. ET (2:00 p.m. PT) on March 26, 2008 and will be hosted by Anthony DiTonno, President and Chief Executive Officer, and Stephen Ghiglieri, Chief Financial Officer.

To participate in the conference call, please dial 1-877-407-0789 (USA) or 1-201-689-8562 (International). In addition, a dial-up replay of the conference call will be available beginning March 26, 2008 at 8:00 p.m. ET (5:00 p.m. PT) and ending on April 5, 2008. The replay telephone number is 1- 877-660-6853 (USA) or 1-201-612-7415 (International), Account Number: 3055, Conference ID Number: 275941.

A live web cast of the call will also be available from the Investor Relations section on the corporate web site at http://www.neurogesx.com. A web cast replay can be accessed on the corporate web site beginning March 26, 2008 at approximately 6:00 p.m. ET. The replay will remain available until April 26, 2008.

About NeurogesX, Inc.

NeurogesX (Nasdaq: NGSX) is a biopharmaceutical company focused on developing and commercializing novel pain management therapies. Its initial focus is on chronic peripheral neuropathic pain, including postherpetic neuralgia (PHN), painful HIV-distal sensory polyneuropathy (HIV-DSP) and painful diabetic neuropathy (PDN). NeurogesX' late stage product portfolio is led by its product candidate NGX-4010, a dermal patch designed to manage pain associated with peripheral neuropathic pain conditions, that the company believes offers significant advantages over other pain therapies.

Safe Harbor Statement

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). NeurogesX disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to, statements concerning future presentations by NeurogesX and the expected benefits of NeurogesX' potential products, including its lead product candidate NGX-4010. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, past results of clinical trials may not be indicative of future clinical trials results; NeurogesX' product candidate may have unexpected adverse side effects or inadequate therapeutic efficacy; positive results in clinical trials may not be sufficient to obtain FDA or European regulatory approval; physician or patient reluctance to use NGX-4010, if approved, or the inability of physicians to obtain sufficient reimbursement for such procedures; potential alternative therapies; maintaining adequate patent or trade secret protection without violating the intellectual property rights of others; and other difficulties or delays in clinical development, obtaining regulatory approval, market acceptance and commercialization of NGX-4010 and the advantages of NGX-4010 over other pain therapies. For further information regarding these and other risks related to NeurogesX' business, investors should consult NeurogesX' filings with the Securities and Exchange Commission.

NeurogesX, Inc. The Ruth Group

Stephen Ghiglieri Investors / Media

(650) 358-3300 Stephanie Carrington / Jason Rando

(646) 536-7017 / 7025

scarrington@theruthgroup.com

jrando@theruthgroup.com


'/>"/>
SOURCE NeurogesX, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. NeurogesX to Present at Roth 2008 OC Growth Stock Conference
2. NeurogesX to Present at the 10th Annual BIO CEO & Investor Conference
3. NeurogesX Closes $25 Million Private Placement
4. NeurogesX, Inc. Announces $25 Million Private Placement
5. NeurogesX to Present at Lazard Capital Markets Healthcare Conference
6. NeurogesX to Present at CIBC World Markets 18th Annual Healthcare Conference and Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
7. NeurogesX Expands Senior Management Team
8. NeurogesX to Present at UBS 2007 Global Life Sciences Conference
9. NeurogesX Appoints New Director to the Board
10. NeurogesX to Present at BioCenturys NewsMakers in the Biotech Industry Conference
11. Vion Reports 2007 Fourth Quarter and Year-End Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... December 01, 2016 , ... ... systems for North American hospitals, will present its chain-of-custody solution for tracking and ... in Las Vegas, Nev., Dec. 4-8, 2016. , Aerocom has a proven solution ...
(Date:12/2/2016)... ... December 01, 2016 , ... Orthogonal, a Chicago-based medical device ... Class II 510(k) clearance for their flagship medical device, SimplECG. , With this ... devices that rely on cloth-based nanosensors. While other companies have attempted to focus ...
(Date:12/2/2016)... The immunohistochemistry (IHC) market is projected ... of 7.3% during the forecast period of 2016 to 2021 dominated ... accounted for the largest share of immunohistochemistry (IHC) market, by end ... , , ... market spread across 225 pages, profiling 10 companies and supported with ...
(Date:11/30/2016)... 2016 The global Pyrogen Testing ... a dominant share in the overall market. The leading ... and Merck KGaA, held a lion,s share of 51% ... observes that these companies are expected to retain their ... are do not require rabbit pyrogen testing along with ...
Breaking Biology Technology:
(Date:6/9/2016)... , June 9, 2016  Perkotek an innovation leader in attendance control systems ... seamlessly log work hours, for employers to make sure the right employees are actually ... http://photos.prnewswire.com/prnh/20160609/377486LOGO ... ... ...
(Date:6/3/2016)... , June 3, 2016 ... von Nepal hat ... Lieferung hochsicherer geprägter Kennzeichen, einschließlich Personalisierung, Registrierung ... in der Produktion und Implementierung von Identitätsmanagementlösungen. ... Ausschreibung im Januar teilgenommen, aber Decatur wurde ...
(Date:6/2/2016)... -- Perimeter Surveillance & Detection Systems, Biometrics ... Support & Other Service  The latest report ... analysis of the global Border Security market . ... $17.98 billion in 2016. Now: In November ... software and hardware technologies for advanced video surveillance. ...
Breaking Biology News(10 mins):